In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates

BACKGROUND: Aztreonam/avibactam is one of the last therapeutic options for treating infections caused by NDM-like-producing Enterobacterales. However, PBP3-modified and NDM-producing Escherichia coli strains that co-produce CMY-42 have been shown to be resistant to this drug combination. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Terrier, Christophe, Nordmann, Patrice, Sadek, Mustafa, Poirel, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154122/
https://www.ncbi.nlm.nih.gov/pubmed/36921067
http://dx.doi.org/10.1093/jac/dkad061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154122/
https://www.ncbi.nlm.nih.gov/pubmed/36921067
http://dx.doi.org/10.1093/jac/dkad061

Ejemplares similares